OVERVIEW
Multi-center, Canadian, Non-interventional, Cohort Study of the Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) (BIC-STaR)
PROTOCOL SUMMARY
The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA <50 copies/mL, at 12 months after initiating or switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide (B/F/TAF).
View moreParticipation requirements
Age
18 years +
Sex
All
Healthy Volunteers
No
Age
18 years +
Sex
All
Healthy Volunteers
No
Study details
Medical Condition
HIV-1-infection
Gender
N/A
Date
November 2018 - June 2024
Study Type
Observational
Study Phase
Product
B/F/TAF
Eligibility information
Inclusion criteria
- HIV-1 infection
- Signed informed consent
- Initiating treatment with B/F/TAF in accordance with the product monograph
Exclusion criteria
- Participation in any other observational or interventional clinical trial without prior approval from the Medical Monitor
Locations
Locations (6)
St. Clair Medical Association/Balmoral Clinic
Toronto, Canada, M4T3A7
Join Gilead Trial Connect and help advance clinical research. Your participation is key to developing future treatments.
Share Trial